← Back to patent-cliff list
Molidustat Sodium
Tier C — Watch / tradeMolidustat Sodium
Bayer
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HIF-PHs
Brand：MUSREDO, マスーレッド
Indications (approved)：Chronic renal impairment, Anaemia
Regional status
US
No progress
2013-10-28
EU
No progress
2014-01-28
China
IND filed
2013-09-23
Japan
Approved
2021-01-22
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Molidustat Sodium?
Approved indications include: Chronic renal impairment, Anaemia.
When does the Molidustat Sodium patent expire?
No public expiry year is available for Molidustat Sodium yet; this page updates once verified.
How do I get a quote for Molidustat Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01